Abstract
Colorectal cancer is one of the most common types of cancer and has a high mortality rate, making accurate prediction of clinical prognosis an important concern. This study sought to investigate the expression of two proteins, MMP-11 and VEGF-C, in colorectal adenocarcinoma tissues to provide options for better tumor detection. The correlation of the expression of these proteins with the clinical and pathological features of colorectal adenocarcinoma and with the invasion and metastasis of colorectal adenocarcinoma were assessed. Immunohistochemistry with light microscopy was used to detect the expression level of MMP-11 and VEGF-C in 78 samples of colorectal adenocarcinoma tissues and in 20 samples of normal colorectal tissues. Expression of MMP-11 in colorectal adenocarcinoma tissues and normal colorectal tissues was detected in 55.1% and 30.0% of samples, respectively; VEGF-C was detected in 78.2% and 15.0% of samples, respectively. The expression of MMP-11 and VEGF-C in colorectal adenocarcinoma tissues were not related to patient age, sex, or tumor location. However, expression was related to Dukes’ staging and lymph node metastasis. Expression of MMP-11 was correlated with distant metastasis from tumors. Lastly, expression of MMP-11 in colorectal adenocarcinoma was positively correlated with VEGF-C. In brief, expression of MMP-11 and VEGF-C in colorectal adenocarcinoma tissues serves as a significant index for evaluating the degree of malignancy, clinical stages, lymph nodes, and distant metastasis of colorectal adenocarcinoma. The detection of both of these proteins may help predict the infiltration, metastasis, and prognosis of colorectal adenocarcinoma, and potentially offers new targets for clinical treatment.
Keywords: MMP-11, VEGF-C, colorectal adenocarcinoma, immunohistochemistry
Introduction
Colorectal cancer is one of the most common malignant tumors of the digestive tract, and its poor prognosis results from infiltration, metastasis, and postoperative recurrence. The extracellular matrix (ECM) acts as a barrier to tumor cell infiltration and metastasis [1]. ECM is degraded by matrix metalloproteinases (MMPs) like MMP-11 [2], which is synthesized and secreted by tumor and connective tissues. MMPs are mainly composed of five classes: stromelysins, membrane type metalloproteinases, gelatinases, collagenases, and other secreted type MMPs [2]. MMP-11 belongs to the stromelysins, which were first discovered in the interstitial cells of breast cancer [3,4]. MMP-11 participates in various pathophysiological processes involving matrix degradation and tumor metastasis, and is the most important proteolytic enzyme for ECM degradation [5]. It can degrade various fibrous connective tissues, destroying the tissue barrier and facilitating the invasion and infiltration of tumors; its expression is up-regulated in various tumors [6-8]. It has been proposed that inhibiting MMP-11 expression could inhibit tumor cell proliferation [9].
Human vascular endothelial growth factor-C (VEGF-C), also called a lymphangiogenic growth factor, belongs to the vascular endothelial growth factor family along with VEGF-A, VEGF-B, and VEGF-D. VEGF proteins control vascularization, vasculogenesis, vascular permeability changes, lymphangiogenesis lymphatic vessel density, and endothelial cell survival of tumors [10]. VEGF-C plays an important role in regulating lymphangiogenesis and is also closely related to tumor invasion and metastasis [11]. It also functions in determining the lymphatic vessel density of tumors [12]. Lymph node metastasis is one of the major routes for the invasion and metastasis of tumors and is closely dependent on the activity of VEGF-C and relevant factors. It has been proposed that the high expression of VEGF-C promoted lymphatic metastasis from tumors by promoting neo-lymphangiogenesis and activating existing lymphatic vessels [13,14].
The known and potential roles of MMP-11 and VEGF-C make them attractive candidates as predictors of cancer progression. In this study, immunohistochemistry was used to detect the expression of MMP-11 and VEGF-C in 78 cases of colorectal adenocarcinoma and in 20 normal colorectal mucosal tissues. We also investigated the relationship of MMP-11 and VEGF-C expression with various clinical and pathological factors, as well as the correlation between the expression of MMP-11 and the expression of VEGF-C. The results offer potential new prognostic and diagnostic factors.
Materials and methods
Human tissues
Tissue samples were obtained from 78 confirmed colorectal adenocarcinomas resected between January and December 2013 and assessed in The Department of Pathology, The First Affiliated Hospital of Zhengzhou University (Zhengzhou, China). None of the patients underwent chemotherapy or radiotherapy. The samples were obtained from 52 males and 26 females (mean age, 47.1 ± 3.3 years; range, 36 to 73 years). Of the 78 samples, 33 were obtained from recta and 45 were from colons. Samples were assessed histologically; 9 samples were of Grade I, 46 were Grade II, and 23 were Grade III. Samples were also assessed for Dukes’ staging: 3 samples were in Stage A, 39 were in Stage B, 27 were in Stage C, and 9 were in Stage D. Of the 78 samples, 28 underwent lymph node metastasis and 9 underwent distant metastasis. For a control group, 20 samples of normal colorectal mucosal tissues were obtained during the same time period.
Reagents
Rabbit anti-human MMP-11 monoclonal antibody and rabbit anti-human VEGF-C polyclonal antibody were purchased from Beijing Zhongshan Golden Bridge Biotechnology Co., Ltd (Beijing, China). An immunohistochemistry kit and a DAB chromogenic reagent were purchased from Fuzhou Maixin Biotechnology Development Co., Ltd (Fuzhou, China).
Immunohistochemistry
All tissue samples were fixed with 10% neutral formalin, embedded in paraffin, and cut into 4-μm serial sections using a microtome. Sections were collected onto glass slides, dewaxed with xylene, dehydrated in a graded alcohol series, and subjected to heat-mediated antigen retrieval. The samples were then incubated overnight in 0.3% H2O2 at room temperature with primary antibodies (MMP-11 or VEGF-C), washed with PBS, incubated with biotin-labeled secondary antibody, and washed with PBS again. The samples were then treated with horseradish peroxidase-labeled working solution of streptavidin and incubated at 37°C for 45 minutes. Next, the samples were developed with DAB color-producing reaction, where the chromogenic time was controlled through microscopic observation. Finally, the samples were stained with haematine, cleared with xylene, and sealed with neutral resins. The sections of known positive colorectal adenocarcinoma were used as positive controls and samples with PBS solution substituted for the primary antibody were used as negative controls.
Quantification of immunohistochemical staining results
Two experienced pathologists performed blind assessment of each section by examining 10 high-power fields of vision that were randomly selected under a microscope (Olympus, BX51-P). Samples were scored for the proportion of positive cells stained: a score of 0 for ≤ 1% positive, 1 for 2%-20%, 2 for 21%-50%, and 3 for ≥ 51%. Samples were also scored for staining intensity: a 0 score for no staining, a 1 for lightly staining, and a 2 for deeply staining. A semi-quantitative analysis was performed by combining the scores for staining and intensity by multiplying the two scores together. With this combined score, ≤ 1.9 indicated negative result (-), 2-2.9 indicated weakly positive result (+), 3-3.9 indicated positive result (++), and ≥ 4 indicated strongly positive result (+++).
Statistical analysis
Statistical analysis was performed using SPSS 18.0 statistical software (IBM, New York City, USA). A χ2 test was performed to compare the expression of MMP-11 and VEGF-C between groups, and a Spearman rank correlation was used to analyze the correlation between MMP-11 and VEGF-C expression.
Results
Expression of MMP-11 and VEGF-C in colorectal adenocarcinoma tissues and normal colorectal mucosal tissues
MMP-11 and VEGF-C proteins were mainly localized within the cytoplasm and were observable as brown or tan granules. MMP-11 was expressed in 55.1% of colorectal adenocarcinoma tissues but in 30.0% of normal colorectal tissues (Table 1); this difference in the percentage of samples expressing MMP-11 was significantly different (p < 0.05). VEGF-C was detected in 78.2% of colorectal adenocarcinoma tissues and 15.0% of controls (Table 1); this difference was also significantly different.
Table 1.
Tissue type | n | MMP-11a | VEGF-Cb |
---|---|---|---|
| |||
Positive expression (%) | Positive expression (%) | ||
Colorectal adenocarcinoma | 78 | 43 (55.1) | 61 (78.2) |
control | 20 | 6 (30.0) | 3 (15.0) |
p = 0.045, χ2 = 4.021;
p = 0.000, χ2 = 29.639.
MMP-11 and VEGF-C expression correlate with clinical and pathological factors of colorectal adenocarcinoma
The expression of MMP-11 was correlated with several known clinical and pathological factors of colorectal adenocarcinoma. The expression of MMP-11 in colorectal adenocarcinoma tissues was related to Dukes’ staging, lymph node metastasis, and distant metastasis (p < 0.05; Table 2). Alternatively, VEGF-C expression was related to histological grading, Dukes’ staging, and lymph node metastasis (p < 0.05; Table 3).
Table 2.
clinicopathological factors | n | MMP-11 | |||||
---|---|---|---|---|---|---|---|
|
|||||||
Positive samples | Negative samples | Positive expression (%) | χ2 value | P value | |||
ages | |||||||
≤ 50 | 47 | 29 | 18 | 61.7 | 2.066 | 0.151 | P > 0.05 |
> 50 | 31 | 14 | 17 | 45.2 | |||
gender | |||||||
male | 52 | 31 | 21 | 59. 6 | 1.270 | 0.260 | P > 0.05 |
female | 26 | 12 | 14 | 46. 2 | |||
tumor location | |||||||
rectal carcinoma | 33 | 17 | 16 | 51.5 | 0.302 | 0.583 | P > 0.05 |
colon carcinoma | 45 | 26 | 19 | 57.8 | |||
histological grading | |||||||
Grade I | 9 | 3 | 6 | 33.3 | 3.828 | 0.147 | P > 0.05 |
Grade II | 46 | 24 | 22 | 52.2 | |||
Grade III | 23 | 16 | 7 | 69. 6 | |||
Dukes’ staging | |||||||
A-B stage | 42 | 18 | 24 | 42.9 | 5.539 | 0.019 | P < 0.05 |
C-D stage | 36 | 25 | 11 | 69.4 | |||
lymphatic metastasis | |||||||
exist | 28 | 19 | 9 | 67.9 | 4.692 | 0.030 | P < 0.05 |
none | 50 | 24 | 26 | 48.0 | |||
distant metastasis | |||||||
exist | 9 | 8 | 1 | 88.9 | 4.688 | 0.030 | P < 0.05 |
none | 69 | 35 | 34 | 50.7 |
Table 3.
Clinicopathological factors | n | VEGF-C | |||||
---|---|---|---|---|---|---|---|
|
|||||||
Positive cases | Negative cases | Positive expression (%) | χ2 value | p value | |||
ages | |||||||
≤ 50 | 47 | 39 | 8 | 83.0 | 1.518 | 0.209 | P > 0.05 |
> 50 | 31 | 22 | 9 | 71.0 | |||
gender | |||||||
male | 52 | 44 | 8 | 84.6 | 3.761 | 0.052 | P > 0.05 |
female | 26 | 17 | 9 | 65.4 | |||
tumor location | |||||||
rectal carcinoma | 33 | 24 | 9 | 72.7 | 1.007 | 0.316 | P > 0.05 |
colon carcinoma | 45 | 37 | 8 | 82.2 | |||
histological grading | |||||||
Grade I | 9 | 4 | 5 | 44.4 | 7.186 | 0.028 | P < 0.05 |
Grade II | 46 | 37 | 9 | 73.9 | |||
Grade III | 23 | 20 | 3 | 87.0 | |||
Dukes’ staging | |||||||
A-B stage | 42 | 28 | 14 | 66.7 | 7.108 | 0.008 | P < 0.05 |
C-D stage | 36 | 33 | 3 | 91.7 | |||
lymphatic metastasis | |||||||
exist | 28 | 27 | 1 | 96.4 | 8.510 | 0.004 | P < 0.05 |
none | 50 | 34 | 16 | 68.0 | |||
distant metastasis | |||||||
exist | 9 | 9 | 0 | 100.0 | 2.835 | 0.092 | P > 0.05 |
none | 69 | 52 | 17 | 75.4 |
Correlation between the expression of MMP-11 and VEGF-C in colorectal adenocarcinoma
The expression of MMP-11 was positively correlated with the expression of VEGF-C (r = 0.273, p = 0.016; Table 4).
Table 4.
MMP-11 | VEGF-C | p value | r value | |
---|---|---|---|---|
| ||||
Positive | Negative | |||
positive | 38 | 5 | 0.016 | 0.273 |
negative | 23 | 12 |
Discussion
Colorectal cancer ranks third in the incidence of cancer and ranks fourth in mortality [15], so improving diagnostic and prognostic factors for this type of cancer is important. The results of this study indicate that both MMP-11 and VEGF-C may be useful as diagnostic or prognostic markers in colorectal cancer.
Both MMP-11 and VEGF-C expression were more common in colorectal adenocarcinoma tissues than in normal tissues. Additionally, the expression of MMP-11 was closely related to the Dukes’ staging, lymph node metastasis, and distant metastasis without a marked correlation with patient age or sex or tumor location. These results indicate that MMP-11 might participate in the process of invasion and infiltration of tumors, and play an important role in lymph node metastasis and distant metastasis from the tumors [16]. VEGF-C expression was related to histological grading, Dukes’ staging, and lymph node metastasis. These results suggest that the increased degree of malignancy of tumors could possibly promote the expression of VEGF-C, thus promoting tumor lymphangiogenesis [17]. The proliferated and expanded lymphatic vessels would then pave the way for the lymph node metastasis from the tumors and allow the tumor cells to pass the neo-lymphatic vessels and enter the lymph nodes. This would allow further expansion toward the whole body, and thereby could promote the further growth of the tumors.
In summary, the expression of MMP-11 and VEGF-C in colorectal adenocarcinoma is associated with infiltration, invasion, and metastasis of these tumors. Additionally, the MMP-11 and VEGF-C expression are positively correlated, indicated that a related pathway may be present between these two proteins. In further studies, MMP-11 and VEGF-C could serve as reference indexes for evaluating the biological behaviors and prognosis of colorectal adenocarcinoma and possibly become a new therapeutic target.
Disclosure of conflict of interest
None.
References
- 1.Groblewska M, Mroczko B, Szmitkowski M. The role of selected matrix metalloproteinases and their inhibitors in colorectal cancer development. Postepy Hig Med Dosw (Online) 2010;64:22–30. [PubMed] [Google Scholar]
- 2.Eiró N, Fernandez-Garcia B, González LO, Vizoso FJ. Cytokines related to MMP-11 expression by inflammatory cells and breast cancer metastasis. Oncoimmunology. 2013;2:e24010. doi: 10.4161/onci.24010. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Basset P, Bellocq JP, Wolf C, Stoll I, Hutin P. Limacher JM, Podhajcer OL, Chenard MP, Rio MC, Chambon P. A novel metalloproteinase gene specifically expressed in stromal cells of breast carcinomas. Nature. 1990;348:699–704. doi: 10.1038/348699a0. [DOI] [PubMed] [Google Scholar]
- 4.Tan J, Buache E, Alpy F, Daguenet E, Tomasetto CL, Ren GS, Rio MC. Stromal matrix metalloproteinase-11 is involved in the mammary gland postnatal development. Oncogene. 2013;21:1034–1038. doi: 10.1038/onc.2013.434. [DOI] [PubMed] [Google Scholar]
- 5.Egeblad M, Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer. 2002;2:161–174. doi: 10.1038/nrc745. [DOI] [PubMed] [Google Scholar]
- 6.Zhao ZS, Chu YQ, Ye ZY, Wang YY, Tao HQ. Over expression of matrix metalloproteinase 11 in human gastric carcinoma and its clinicopathologic significance. Hum Pathol. 2010;41:686–696. doi: 10.1016/j.humpath.2009.10.010. [DOI] [PubMed] [Google Scholar]
- 7.Nonsrijun N, Mitchai J, Brown K, Leksomboon R, Tuamsuk P. Overexpression of matrix metalloproteinase 11 in Thai prostatic adenocarcinoma is associated with poor survival. Asian Pac J Cancer Prev. 2013;14:3331–3335. doi: 10.7314/apjcp.2013.14.5.3331. [DOI] [PubMed] [Google Scholar]
- 8.Wasenius VM, Hemmer S, Kettunen E, Knuutila S, Franssila K, Joensuu H. Hepatocyte growth factor receptor, matrix metalloproteinase-11, tissue inhibitor of metalloproteinase-1, and fibronectin are up-regulated in papillary thyroid carcinoma: a cDNA and tissue microarray study. Clin Cancer Res. 2003;9:68–75. [PubMed] [Google Scholar]
- 9.Deng H, Guo RF, Li WM, Zhao M, Lu YY. Matrix metalloproteinase 11 depletion inhibits cell proliferation in gastric cancer cells. Biochem Biophys Res Commun. 2005;326:274–281. doi: 10.1016/j.bbrc.2004.11.027. [DOI] [PubMed] [Google Scholar]
- 10.Howell WM, Bateman AC, Turner SJ, Collins A, Theaker JM. Influence of vascular endotheliac growth factor single nucleotide polymorphisms on tumor development in cutaneous malignant melanoma. Genes Immun. 2002;3:229–239. doi: 10.1038/sj.gene.6363851. [DOI] [PubMed] [Google Scholar]
- 11.Han FH, Li HM, Zheng DH, He YL, Zhan WH. The effect of the expression of vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 on the clinical outcome in patients with gastric carcinoma. Eur J Surg Oncol. 2010;36:1172–1179. doi: 10.1016/j.ejso.2010.09.002. [DOI] [PubMed] [Google Scholar]
- 12.Gao S, Ma JJ, Lu C. Prognostic significance of VEGF-C immunohistochemical expression in breast cancer: a meta-analysis. Tumour Biol. 2014;35:1523–1529. doi: 10.1007/s13277-013-1211-3. [DOI] [PubMed] [Google Scholar]
- 13.Duff SE, Jeziorska M, Kumar S, Haboubi N, Sherlock D, O’dwyer ST, Jayson GC. Lymphatic vessel density, microvessel density and lymphangiogenic growth factor expression in colorectal cancer. Colorectal Dis. 2007;9:793–800. doi: 10.1111/j.1463-1318.2006.01199.x. [DOI] [PubMed] [Google Scholar]
- 14.Szajewski M, Kruszewski WJ, Lakomy J, Ciesielski M, Kawecki K, Jankun J, Buczek T, Szefel J. VEGF-C and VEGF-D overexpression is more common in left-sided and well-differentiated colon adenocarcinoma. Oncol Rep. 2014;31:125–130. doi: 10.3892/or.2013.2821. [DOI] [PubMed] [Google Scholar]
- 15.Martins SF, Garcia EA, Luz MA, Pardal F, Rodrigues M, Filho AL. Clinicopathological correlation and prognostic significance of VEGF-A, VEGF-C, VEGFR-2 and VEGFR-3 expression in colorectal cancer. Cancer Genomics Proteomics. 2013;10:55–67. [PubMed] [Google Scholar]
- 16.Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential ther-apeutic targets in human cancer. Clin Oncol. 2009;27:5287–5297. doi: 10.1200/JCO.2009.23.5556. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Li X, Liu B, Xiao J, Yuan Y, Ma J, Zhang Y. Roles of VEGF-C and Smad4 in the Lymphangiogenesis, Lymphatic Metastasis, and Prognosis in Colon Cancer. J Gastrointest Surg. 2011;15:2001–2010. doi: 10.1007/s11605-011-1627-2. [DOI] [PubMed] [Google Scholar]